AdvaMed Asks For Changes In Guidance On PMA Pre-Approval Inspections
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed is recommending that FDA be both more flexible and more specific in its policies on manufacturing inspections conducted as part of the premarket approval process
You may also be interested in...
FDA Guidance Gives Timelines For PMA Manufacturing Audits
FDA released final 1guidance on facility inspection policies for premarket approval applications Jan. 8, putting on paper inspection timeline commitments that allow PMA reviewers to meet user fee performance goal deadlines
FDA Guidance Gives Timelines For PMA Manufacturing Audits
FDA released final 1guidance on facility inspection policies for premarket approval applications Jan. 8, putting on paper inspection timeline commitments that allow PMA reviewers to meet user fee performance goal deadlines
Guidance Sets FDA Deadlines For PMA Preapproval Factory Inspections
FDA gives itself 140 days to review a PMA manufacturing section and inspect the firm's manufacturing operations under a 1draft guidance issued June 19